• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Atea Pharmaceuticals Inc.

    4/27/26 4:57:59 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVIR alert in real time by email
    DEFA14A 1 avir-defa_14a-2026.htm DEFA14A DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities
    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to §240.14a‑12

     

    ATEA PHARMACEUTICALS, INC.

    (Name of Registrant as Specified In Its Charter)

    _____________________________________________________________________________________________
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required
    ☐ Fee paid previously with preliminary materials
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a‑6(i)(1) and 0‑11

     


     

     

    img195764037_0.jpg

    Your Vote Counts! ATEA PHARMACEUTICALS, INC. 2026 Annual Meeting Vote by June 17, 2026 11:59 PM ET ATEA PHARMACEUTICALS, INC. 225 FRANKLIN STREET, SUITE 2100 BOSTON, MA 02110 V93924-P52208 You invested in ATEA PHARMACEUTICALS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote Virtually at the Meeting* June 18, 2026 9:00 AM, EDT Smartphone users Point your camera here and vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/AVIR2026 *Please check the meeting materials for any special requirements for meeting attendance.

     


     

     

    img195764037_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. Election of Class III Directors For Nominees: 01) Jerome Adams, MD, MPH 02) Howard Berman, PhD 03) Barbara Duncan 2. Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. For NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment of the Annual Meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V93925-P52208

     

     


    Get the next $AVIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVIR

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    More analyst ratings

    $AVIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

    BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating h

    5/27/26 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

    BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain. The presentations include two posters supporting Atea's fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented and d

    5/13/26 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

    C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026 Encouraging Preclinical Data Support AT-587 as a Potential First-in-Class Therapy for Hepatitis E Virus (HEV); Phase 1 Initiation Expected Mid-2026 Company Holding Conference Call Today at 4:30 pm ET BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of ora

    5/12/26 4:05:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)

    4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    5/21/26 6:30:02 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)

    4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    5/20/26 4:15:21 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Corcoran Andrea exercised 60,000 shares at a strike of $1.24, increasing direct ownership by 8% to 823,576 units (SEC Form 4)

    4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    3/13/26 6:00:09 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously

    8/13/24 7:25:26 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals downgraded by JP Morgan

    JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight

    8/10/23 6:17:18 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

    JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously

    3/2/22 10:09:39 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    SEC Filings

    View All

    SEC Form 10-Q filed by Atea Pharmaceuticals Inc.

    10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

    5/12/26 4:45:37 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

    5/12/26 4:17:39 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.

    SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    5/6/26 11:00:56 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)

    4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    5/21/26 6:30:02 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)

    4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    5/20/26 4:15:21 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

    4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    1/17/25 2:30:36 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Financials

    Live finance-specific insights

    View All

    Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

    C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026 Encouraging Preclinical Data Support AT-587 as a Potential First-in-Class Therapy for Hepatitis E Virus (HEV); Phase 1 Initiation Expected Mid-2026 Company Holding Conference Call Today at 4:30 pm ET BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of ora

    5/12/26 4:05:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

    BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website a

    5/5/26 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care Expanded Antiviral Pipeline with New Hepatitis E Virus (HEV) Program; Lead Product Candidate AT-587 Expected

    3/5/26 4:05:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Leadership Updates

    Live Leadership Updates

    View All

    ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

    ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Howard Berman, Ph.D., as Executive Chairman of the ReAlta Life Sciences Board of Directors, effective immediately. "We are delighted to welcome Howard to ReAlta at a pivotal moment for the Company as we move towards meaningful catalysts," said Kenji Cunnion, M.D., MPH, Co-Founder, Chief Medical Officer and Board Member of ReAlta. "His proven track record in advancing innovative immunology-based therapies and creatin

    11/25/25 8:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

    BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

    4/17/25 7:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    $AVIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    11/15/24 10:34:54 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    11/12/24 9:50:14 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    2/15/24 11:35:08 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care